解读CDK4突变对口腔状细胞癌中abemaciclib结合的差异影响:一种精确医学方法
1Department of Stomatology, Nantong Integrated Traditional Chinese and Western Medicine Hospital, Nantong, Jiangsu, China.
Irish journal of medical science
|July 21, 2025
概括
口腔癌的耐药性是一个挑战. 像T102K和P110L这样的CDK4突变削弱了abemaciclib的结合,这表明潜在的治疗耐药性和需要新的治疗方法.
科学领域:
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 精准医学旨在量身定制治疗,但面临着药物耐药性.
- 了解导致药物耐药性的突变是开发先进治疗方法的关键.
- 循环素依赖性激酶-4 (CDK4) 突变与口腔状细胞癌 (OSCC) 的发展有关.
研究的目的:
- 为了研究CDK4抑制剂abemaciclib与野生类型和突变CDK4.4的生物物理结合动态.
- 为了确定影响abemaciclib结合稳定性和有效性的特定CDK4突变.
主要方法:
- 采用分子动力学模拟来分析结合相互作用.
- 专注于CDK4链环区域,检查D99G,R101M,T102K和P110L的突变.
- 评估了自由能源景观的变化,结构波动和键相互作用.
主要成果:
- CDK4突变D99G和R101M保持了稳定的abemaciclib相互作用.
- 突变T102K和P110L显著降低了abemaciclib的结合稳定性.
- 削弱的结合与改变的能量格局,增加的波动和更少的键相关.
结论:
- 患有T102K和P110L CDK4突变的患者可能会对abemaciclib产生抗性.
- 对于患有这些特定突变的患者,需要使用替代治疗策略.
- 进一步的研究对于基于遗传特征的个性化癌症治疗至关重要.
相关概念视频
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:15M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K